Article (Scientific journals)
Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
Jerusalem, Guy; Beguin, Yves; Fassotte, Marie-France et al.
2000In Haematologica, 85 (6), p. 613-8
Peer Reviewed verified by ORBi
 

Files


Full Text
128.pdf
Publisher postprint (122.34 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Disease Progression; Female; Fluorine Radioisotopes/diagnostic use; Fluorodeoxyglucose F18/diagnostic use/pharmacokinetics; Humans; Lymphoma, Non-Hodgkin/diagnosis/drug therapy/metabolism; Male; Middle Aged; Predictive Value of Tests; Prognosis; Radiopharmaceuticals/pharmacokinetics; Survival Rate; Tomography, Emission-Computed; Treatment Outcome
Abstract :
[en] BACKGROUND AND OBJECTIVE: Early recognition of the ineffectiveness of chemotherapy could result in lower cumulative drug toxicity and tumor burden at the start of salvage therapy, which might improve clinical outcome. Therefore, we studied the value of (18)F-FDG PET for early evaluation of response in patients with non-Hodgkin's lymphoma (NHL). DESIGN AND METHODS: We studied 28 patients by (18)F-FDG PET after a median of 3 cycles of polychemotherapy. The presence or absence of abnormal (18)F-FDG uptake was correlated to clinical outcome (median follow-up: 17.5 months, range 4-47 months). RESULTS: Five of 28 patients still had increased (18)F-FDG uptake in one or more sites previously shown to be involved by lymphoma at baseline evaluation. Only one of these five patients entered complete remission (CR), whereas among the 23 patients with negative (18)F-FDG PET studies, two died of toxicity during chemotherapy and all the others entered clinical CR (p<0.00001). All five patients with and 7/21 patients without residual abnormal (18)F-FDG uptake relapsed or reprogressed (positive predictive value for relapse: 100%, negative predictive value: 67%). By Kaplan-Meier analysis, progression-free survival (PFS) at 1 and 2 years was respectively 20+/-18% and 0% for (18)F-FDG PET positive patients and 81+/-9% and 62+/-12% for (18)F-FDG PET negative patients (p=0.0001). Overall survival (OS) at 1 and 2 years was respectively 20+/-18% and 0% for (18)F-FDG PET positive and 87+/-7% and 68+/-11% for (18)F-FDG PET negative patients (p<0.0001). INTERPRETATION AND CONCLUSIONS: Persistent tumoral (18)F-FDG uptake after a few cycles of polychemotherapy is predictive of CR, PFS and OS in NHL. Further studies are warranted to determine whether (18)F-FDG PET has a predictive value independent from conventional prognostic factors. However, the sensitivity of qualitative (18)F-FDG PET imaging in identifying patients with a poor outcome was insufficient. Earlier evaluation after only one cycle of chemotherapy and quantitative analysis might increase the sensitivity of 18F-FDG PET is predicting treatment failure.
Disciplines :
Hematology
Author, co-author :
Jerusalem, Guy  ;  Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Beguin, Yves  ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Fassotte, Marie-France ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Najjar, F.
Paulus, P.
Rigo, Pierre ;  Université de Liège - ULiège > Département des sciences de la motricité > Pathologie générale et médecine nucléaire
Fillet, Georges ;  Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique
Language :
English
Title :
Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
Publication date :
2000
Journal title :
Haematologica
ISSN :
0390-6078
eISSN :
1592-8721
Publisher :
Ferrata Storti Foundation, Pavia, Italy
Volume :
85
Issue :
6
Pages :
613-8
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 23 March 2009

Statistics


Number of views
65 (3 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
202
Scopus citations®
without self-citations
186

Bibliography


Similar publications



Contact ORBi